Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Global Healthcare ETF (NY:IXJ)

100.84 +0.97 (+0.97%)
Streaming Delayed Price Updated: 3:10 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about iShares Global Healthcare ETF

< Previous 1 2 Next >
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? ↗
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The... 
Via The Motley Fool
Topics ETFs
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
Via Stocktwits
Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report ↗
Via Stocktwits
Topics Government
Trump Walks Back Plan To Slap Tariffs On Generic Drugs After White House Clash Over Prices, Supply Risks: Report ↗
Via Stocktwits
Topics Government
News headline image
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗
One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains. 
Via The Motley Fool
Topics ETFs
News headline image
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors? ↗
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? ↗
One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies. 
Via The Motley Fool
Topics ETFs
CDC In Crisis: Kennedy Pressured To Quit As States Revolt Over Vaccine Board Shake-Up ↗
Via Stocktwits
Trump’s Big Pharma Tariff Call Delayed Again As White House Juggles Trade Battles And Diplomatic Showdowns: Report ↗
Via Stocktwits
Topics Government
Trump Plans Gradual Tariff Hike On Imported Pharma To 250% Over 18 Months To Boost US Production ↗
Via Stocktwits
Topics Government
News headline image
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? ↗
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return. 
Via The Motley Fool
Topics ETFs
News headline image
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points. 
Via The Motley Fool
Topics ETFs
News headline image
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance? 
Via The Motley Fool
Topics ETFs
News headline image
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF ↗
IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? ↗
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors. 
Via The Motley Fool
Topics ETFs
News headline image
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ ↗
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S.... 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles. 
Via The Motley Fool
Topics ETFs
News headline image
INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally? ↗
According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
News headline image
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul ↗
Via MarketBeat
News headline image
Trump Admin Targets Medicaid Spending On Immigrants, Threatening Over $12 Billion California Program ↗
The Trump administration is investigating Medicaid spending in California and other Democrat-led states over potential misuse in immigrant healthcare programs. 
Via Benzinga
Topics Government
News headline image
Trump Pollster Quietly Tells Republicans: Voters Still Trust Childhood Vaccines, Doubt COVID Shots ↗
The Fabrizio Ward survey of 1,000 voters found 77% of Trump supporters back measles shots and 69% support hepatitis B, while at least 90% of Kamala Harris voters backed all three vaccines. 
Via Stocktwits
Topics ETFs Government
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗
Via Stocktwits
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.